Tissue Regenix Group Ltd is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.
www.tissueregenix.com
Tissue Regenix Group Auction Details
The Ordinary Shares of Tissue Regenix Group Ltd were admitted to trading on Asset Match on 7 January 2025 at a price of X pence per share (TBC).
Auctions are to be held quarterly and close at 4pm on the last Tuesday of each month (unless stated otherwise).
The tick size for this company is XX pence per share (TBC).
Participants can send orders via their existing broker. Further details can be found by clicking on the "Auction instructions" section below.